Rigel Pharmaceuticals announced that final Phase 3 trial data for GAVRETO (pralsetinib) as a first-line treatment for RET fusion-positive non-small cell lung cancer (NSCLC) will be presented at ASCO 2026, showing improved progression-free survival and response rates over standard care. Additionally, data from Phase 1/2 trials of pralsetinib in RET-altered thyroid cancer and real-world evidence supporting REZLIDHIA (olutasidenib) for relapsed/refractory IDH1-mutated acute myeloid leukemia (AML) were presented. These findings highlight the clinical relevance of Rigel's oncology portfolio and suggest olutasidenib may be an effective post-venetoclax therapy for AML patients. The presentations at ASCO and EHA 2026 will further inform treatment strategies for these difficult-to-treat cancers.
AI/R, a technology company specializing in Agentic AI, has deepened its partnership with Databricks, achieving Gold partner status and expanding its certifications from 11 to over 100. This growth enables AI/R to deliver advanced AI and data solution...
New long-term data from the ADjoin trial shows that lebrikizumab, an injectable treatment for moderate to severe atopic dermatitis, maintains skin clearance and reduces itching for up to 2 years even with monthly dosing instead of biweekly. About 76%...
Greystone, a national commercial real estate finance company, has appointed Joshua Rosen as Senior Managing Director to focus on originating loans for seniors housing and healthcare sectors. Based in Chicago, Rosen brings extensive experience from Wa...
Brodsky & Smith LLC announced investigations into the merger agreements of Apogee Therapeutics, Roku, TruBridge, and Organon. Each investigation questions whether the respective company boards fulfilled their fiduciary duties by ensuring a fair proce...
Brodsky & Smith LLC has announced investigations into the merger agreements of Arcosa, Fathom Holdings, Nuvalent, and Dana Incorporated. These investigations focus on whether the respective company boards breached fiduciary duties by failing to ensur...
